Welcome to SAMHSA's Publications site. In the future, you may be asked to respond to a CAPTCHA to access the site for added security.
The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.
This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD.
This information sheet, for practitioners, explains the importance of concurrent treatment of OUD with prenatal/postpartum care and the importance of providing the materials to clients.
This toolkit offers strategies to health care providers, communities, and local governments for developing practices and policies to help prevent opioid-related overdoses and deaths. Access reports for community members, prescribers, patients and families, and those recovering from opioid overdose.
Equipa a los proveedores de atención médica, las comunidades y los gobiernos locales con materiales para desarrollar prácticas y políticas para ayudar a prevenir las sobredosis y las muertes relacionadas con los opioides. Aborda diferentes asuntos de interés para los proveedores de atención médica, personal de primeros auxilios, los proveedores de tratamientos y los que están recuperándose de sobredosis de opioides. Actualizada en el 2018.
This report presents 2016 national estimates of use of alcohol, tobacco products, illicit drugs (such as, marijuana, cocaine, heroin, hallucinogens, and inhalants, as well as the misuse of opioids, prescription pain relievers, tranquilizers, stimulants, and sedatives), substance use disorders, and substance use treatment among people 12 years of age and older. It Includes national estimates of any mental illness, serious mental illness, major depressive episode, use of mental health services and suicidal ideation among adults ages 18 or older and national estimates of major depressive episode, use of mental health services among adolescents aged 12 to 17. Trend information on these topics are also presented.
This handbook provides guidance on using the web-based, multimedia tool Decisions in Recovery: Medications for Opioid Addiction. This handbook and the web-based tool offers information about medication-assisted treatment. Both resources help people living with opioid use disorder compare treatment options and discuss their preferences with a provider.
This manual offers best practices to states, tribes, and local communities on collaborative treatment approaches for pregnant women living with opioid use disorders, and the risks and benefits associated with medication-assisted treatment.
This advisory summarizes data on the use of sublingual and transmucosal buprenorphine for the medication-assisted treatment of opioid use disorder.
This guide explains how to use extended-release injectable naltrexone as part of medication-assisted treatment (MAT) for opioid use disorder. It covers assessing patients, initiating MAT, monitoring progress, and deciding when to end treatment.
Millions of Americans have a substance use disorder. Find a treatment facility near you.
Free and confidential support for people in distress, 24/7.
Find treatment facilities confidentially and anonymously, 24/7.
Treatment referral and information, 24/7.